NCT00003669View on ClinicalTrials.gov

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

November 30, 1998

Study Completion Date

April 30, 2001

Conditions
Endometrial Cancer
Interventions
DRUG

arzoxifene hydrochloride

Trial Locations (10)

10021

Memorial Sloan-Kettering Cancer Center, New York

19001

Abington Memorial Hospital, Abington

43210

Arthur G. James Cancer Hospital - Ohio State University, Columbus

43214

Grant/Riverside Methodist Hospitals, Columbus

63110

Washington University Barnard Cancer Center, St Louis

65203

Ellis Fischel Cancer Center - Columbia, Columbia

73190

University of Oklahoma Health Sciences Center, Oklahoma City

77060

U.S. Oncology, Houston

91109-7013

Huntington Memorial Hospital, Pasadena

27599-7295

Lineberger Comprehensive Cancer Center, UNC, Chapel Hill

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00003669 - Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer | Biotech Hunter | Biotech Hunter